Latest Oncology News

TST001 Under Evaluation in Locally Advanced or Metastatic Solid Tumors

TST001 Under Evaluation in Locally Advanced or Metastatic Solid Tumors

January 23rd 2022

Kristi Rosa

The safety and tolerability of TST001 is under investigation as a potential treatment option for patients with gastric/gastroesophageal junction cancer and other locally advanced or metastatic solid tumors as part of a phase 1 trial.

Nivolumab Plus mFOLFOX6 and Bevacizumab Misses PFS End Point in mCRC

Nivolumab Plus mFOLFOX6 and Bevacizumab Misses PFS End Point in mCRC

January 23rd 2022

Will Pizii

The addition of nivolumab to mFOLFOX6 and bevacizumab failed to demonstrate a statistically significant improvement in progression-free survival vs mFOLFOX6 and bevacizumab alone in previously untreated patients with metastatic colorectal cancer, according to findings from the phase 2/3 CheckMate 9X8 trial.

Trastuzumab Deruxtecan Demonstrates Sustained Efficacy in HER2+ mCRC

Trastuzumab Deruxtecan Demonstrates Sustained Efficacy in HER2+ mCRC

January 22nd 2022

Will Pizii

Trastuzumab deruxtecan demonstrated durable responses and a safety profile that was consistent with findings from the primary analysis of the phase 2 DESTINY-CRC01 trial in pretreated patients with HER2-expressing metastatic colorectal cancer, according to updated results of the study.

Nivolumab/Encorafenib/Cetuximab Triplet Elicits High Response Rate in MSS, BRAF V600E-Mutant mCRC

Nivolumab/Encorafenib/Cetuximab Triplet Elicits High Response Rate in MSS, BRAF V600E-Mutant mCRC

January 22nd 2022

Matthew Fowler

The addition of nivolumab to encorafenib and cetuximab elicited a high response rate and an acceptable safety profile in patients with refractory microsatellite stable, BRAF V600E–mutant metastatic colorectal cancer, according to findings from a phase 1/2 trial.

Regorafenib Plus Pembrolizumab Misses PFS End Point in Microsatellite Stable CRC

Regorafenib Plus Pembrolizumab Misses PFS End Point in Microsatellite Stable CRC

January 22nd 2022

Tony Berberabe, MPH

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

Latest Oncology Videos

All Oncology News

Pembrolizumab Triplet Induces Deep, Durable Responses in Some Patients With Treatment-Refractory mCRC

January 22nd 2022

Ryan McDonald

The use of pembrolizumab plus binimetinib and bevacizumab in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer induced a median progression-free survival of 5.8 months, according to preliminary findings from a phase 2 trial.

Onvansertib Plus FOLFIRI/Bevacizumab Generates Meaningful Responses in KRAS-Mutant mCRC

January 22nd 2022

Nichole Tucker

Onvansertib in combination with irinotecan, fluorouracil, and folinic acid, plus bevacizumab, demonstrated encouraging efficacy and was well-tolerated in patients with KRAS-mutated metastatic colorectal cancer.

Frontline Lenvatinib/TACE Improves OS in Advanced HCC

January 22nd 2022

Hayley Virgil

Transarterial chemoembolization plus lenvatinib led to a significant improvement in overall survival vs lenvatinib alone as frontline therapy in patients with advanced hepatocellular carcinoma, according to findings from the phase 3 LAUNCH trial.

Olaparib Plus Pembrolizumab Demonstrates Manageable AEs in Advanced Cholangiocarcinoma

January 22nd 2022

Conor Killmurray

The combination of olaparib and pembrolizumab demonstrated acceptable safety and an manageable adverse effect profile in patients with advanced cholangiocarcinoma who had received prior gemcitabine-based therapy, according to findings from a phase 2 trial.

Pembrolizumab/Chemo Combo Emerges as Standard of Care in Esophageal Cancer/GEJ Adenocarcinoma

January 21st 2022

Lindsay Fischer

Updated findings from the KEYNOTE-590 study confirmed the clinical benefit of the combination of pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer.

TACE Combined With Lenvatinib and Sunitinib May Be a Safe, Tolerable Treatment Option for Unresectable HCC

January 21st 2022

Colleen Moretti

Transarterial chemoembolization combined with lenvatinib plus sintilimab was safe and effective for patients with unresectable hepatocellular carcinoma.

Lenvatinib May Provide Survival Benefit With Manageable Toxicities in Recurrent HCC After Liver Transplantation

January 21st 2022

Darlene Dobkowski, MA

Lenvatinib was effective in treating patients with recurrent hepatocellular carcinoma after liver transplantation and demonstrated manageable toxicities.

Nivolumab/Chemo Combo Maintains Clinical Efficacy at 2 Years in Gastric/GEJ Cancer

January 21st 2022

Jason Harris

Nivolumab plus chemotherapy demonstrated a durable survival benefit for patients with gastric or gastroesophageal junction cancer, according to updated findings from the CheckMate 649 trial.

Initial Treatment With Lenvatinib Prolongs Survival for Patients With Hepatocellular Carcinoma

January 21st 2022

Jamie Cesanek

Initial treatment with lenvatinib in patients with Barcelona Clinic Liver Cancer stage B2 hepatocellular carcinoma helped prolong survival.

Sintilimab Plus Standard Chemotherapy Misses OS End Point in Metastatic Pancreatic Cancer

January 21st 2022

Jonah Feldman

Sintilimab plus standard-of-care chemotherapy failed to demonstrate a significant improvement in overall survival and progression-free survival vs standard-of-care chemotherapy alone but did result in an improved objective response rate in patients with metastatic or recurrent pancreatic adenocarcinoma, according to findings from the phase 3 CISPD3 trial.

Oral Fluoropyrimidine Improves Survival as Adjuvant Therapy in Biliary Tract Cancer

January 21st 2022

Ariana Pelosci

The oral fluoropyrimidine derivative S-1 led to improved survival when used as adjuvant therapy compared with surgery alone in patients with biliary tract cancers.

Pembrolizumab Plus BSC Produces Improved OS in Advanced HCC

January 21st 2022

Dylann Cohn-Emery

The combination of pembrolizumab plus best supportive care elicited improved overall survival and overall response rates as second-line therapy in patients from Asia with advanced hepatocellular carcinoma.

Adagrasib Monotherapy Elicits High Rates of Disease Control in KRAS-Mutated PDAC and Other GI Malignancies

January 21st 2022

Audrey Sternberg

Adagrasib monotherapy demonstrated encouraging clinical activity in patients with previously treated pancreatic ductal adenocarcinoma and other non–colorectal gastrointestinal tumors that harbor KRAS G12C mutations.

Zanubrutinib sBLA for Waldenström Macroglobulinemia Accepted in China

January 21st 2022

Kristi Rosa

The China National Medical Products Administration has accepted a supplemental new drug application for zanubrutinib as a treatment for adult patients with Waldenström macroglobulinemia.

FDA Grants Orphan Drug Designation to Silmitasertib for Biliary Tract Cancer

January 21st 2022

Kristi Rosa

The FDA has granted an orphan drug designation to silmitasertib for use as a potential therapeutic option in patients with biliary tract cancer.

See All News